Rapid Novor Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
56
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5M
- Investors
-
4
Rapid Novor General Information
Description
Developer of protein sequencing technology designed to develop antibody proteins for pharmaceutical companies. The company's technology produces new antibodies directly from the sample with sequence accuracy and has the same binding affinity and also mass uses spectrometry to restore hybridoma cell line, confirm antibody products, examine post-translational modifications and glycosylations and accelerate biosimilar development, enabling medical researchers to develop and advance life science for better human health with next-generation protein sequencing.
Contact Information
Website
www.rapidnovor.comCorporate Office
- Unit 450
- 137 Glasgow Street
- Kitchener, Ontario N2G 4X8
- Canada
Corporate Office
- Unit 450
- 137 Glasgow Street
- Kitchener, Ontario N2G 4X8
- Canada
Rapid Novor Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 28-Jul-2020 | $5M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 12-Feb-2018 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 20-Jul-2017 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 28-Apr-2015 | Completed | Startup |
Rapid Novor Patents
Rapid Novor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4754534-A1 | Methods for the assembly of protein sequences in complex protein mixtures | Pending | 02-Aug-2023 | ||
| WO-2025024921-A1 | Methods for the assembly of protein sequences in complex proteins mixtures | Inactive | 02-Aug-2023 | ||
| CA-3235238-A1 | Method for detection and quantification of immunoglobulin free light chain dimers | Active | 08-Jul-2022 | ||
| EP-4551946-A1 | Method for detection and quantification of immunoglobulin free light chain dimers | Pending | 08-Jul-2022 | ||
| EP-4551946-A4 | Method for detection and quantification of immunoglobulin free light chain dimers | Pending | 08-Jul-2022 | G01N33/6848 |
Rapid Novor Signals
Rapid Novor Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| China Growth Capital | Venture Capital | Minority | ||
| Co-Win Ventures | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | |||
| University of Waterloo | University |
Rapid Novor FAQs
-
When was Rapid Novor founded?
Rapid Novor was founded in 2015.
-
Where is Rapid Novor headquartered?
Rapid Novor is headquartered in Kitchener, Canada.
-
What is the size of Rapid Novor?
Rapid Novor has 56 total employees.
-
What industry is Rapid Novor in?
Rapid Novor’s primary industry is Drug Discovery.
-
Is Rapid Novor a private or public company?
Rapid Novor is a Private company.
-
What is Rapid Novor’s current revenue?
The current revenue for Rapid Novor is .
-
How much funding has Rapid Novor raised over time?
Rapid Novor has raised $5M.
-
Who are Rapid Novor’s investors?
China Growth Capital, Co-Win Ventures, Johnson & Johnson Innovation - JLABS, and University of Waterloo have invested in Rapid Novor.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process